Table 3

 Evaluation of signal strengthening criteria among outcomes where rate ratios were significantly increased

CriterionBehcet’s syndromeRaynaud’s diseaseType 1 diabetes
Analysis based on 20 or more vaccine exposed casesNo (n=5)Yes (n=37)Yes (n=99)
Rate ratio ≥3.0Yes (3.37)No (1.67)No (1.29)
Significantly increased rate ratios in both countries when analysed separatelyNo (3.38*, 95% CI 0.83 to 13.84 for Sweden (3 exposed cases); 4.63†, 95% CI 0.64 to 33.66 for Denmark (2 exposed cases))No (1.86*, 95% CI 1.19 to 2.89 for Sweden (25 exposed cases); 1.46*, 95% CI 0.64 to 3.33 for Denmark (12 exposed cases))No (1.47*, 95% CI 1.08 to 2.01 for Sweden (47 exposed cases); 1.09*, 95% CI 0.76 to 1.57 for Denmark (52 exposed cases))

*Adjusted for age in two year intervals, calendar year, and parental country of birth, parental education, and paternal socioeconomic status.

†Adjusted for age in two year intervals (model with full adjustment did not converge).